Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RESEARCH TOOLSreports
Rocket Pharmaceuticals (RCKT) Stock Price & Analysis
658 Followers
RCKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.86 - $24.65
Previous Close$20.49
Volume1.44M
Average Volume (3M)1.12M
Market Cap
$1.65B
Enterprise Value$1.37B
Total Cash (Recent Filing)$307.04M
Total Debt (Recent Filing)$25.39M
Price to Earnings (P/E)-6.1
Beta1.57
Next Earnings
Nov 08, 2023EPS Estimate
-$0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.34
Shares Outstanding80,525,531
10 Day Avg. Volume1,104,786
30 Day Avg. Volume1,116,585
Standard Deviation0.18
R-Squared0.13
Alpha-0.00276
Financial Highlights & Ratios
Price to Book (P/B)4.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.14K
Enterprise Value/Ebitda-5.44
Forecast
1Y Price Target
$51.33Price Target Upside163.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Rocket Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $14.86 and its highest was $24.65 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Currently, no data Available
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Nov 08, 2023 which is in 36 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Aug 10, 2023. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.809 by -$0.011.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -$0.82.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 80,525,530 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.809. Following the earnings report the stock price went down -1.061%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 87M.
---
Rocket Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.33 (163.91% Upside)
$51.33 (163.91% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $428.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.86%
12-Months-Change
Fundamentals
Return on Equity
-62.86%
Trailing 12-Months
Asset Growth
6.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
Top 5 ETFs holding RCKT
Vanguard Total Stock Market ETF
$29.43M
Vanguard Health Care ETF
$3.07M
Schwab U.S. Broad Market ETF
$651.13K
Fidelity Nasdaq Composite Index ETF
$457.03K
Vanguard Russell 3000 ETF
$54.79K
Up to five ETFs with an Outperform Smart Score that hold RCKT. The ETFs are listed according to market value of RCKT within the ETF
---